...Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) discontinued development of Sollpura liprotamase (LY3031642) after the candidate missed the primary...
...Phase III SOLUTION trial of Sollpura in the indication (see BioCentury, Jan. 6, 2017 ). Sollpura...
...Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Sollpura liprotamase (LY3031642...

...Ph IIa data 2Q18 Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) / Eli Lilly and Co. (NYSE:LLY) Sollpura liprotamase...

...Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) began the Phase III RESULT trial to evaluate oral Sollpura liprotamase (LY3031642...
...9 ). RESULT includes a 20-week extension period for patients randomized to the Sollpura arm. Sollpura...
...Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Sollpura liprotamase (LY3031642...

...data from the open-label, international Phase III SOLUTION trial in 129 patients showed that oral Sollpura...
...CFA following 7 weeks of therapy (95% CI: -16%, -8%). The non-inferiority margin was 15%. Sollpura...
...Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase (Sollpura) (LY3031642...

...Ph III data December Eli Lilly and Co. (NYSE:LLY) / Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) Sollpura liprotamase...

...A DSMB recommended continuation of the open-label, international Phase III SOLUTION trial comparing oral Sollpura vs...
...the trial, which has completed enrollment. Anthera has exclusive, worldwide rights to develop and commercialize Sollpura...
...Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase ( Sollpura ) ( LY3031642...

...Anthera began the open-label, international Phase III SOLUTION trial to compare oral Sollpura vs. oral porcine-derived...
...therapy (PERT) in about 130 patients. Anthera has exclusive, worldwide rights to develop and commercialize Sollpura...
...Hayward, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase ( Sollpura ) ( LY3031642...

...Eli Lilly granted exclusive, worldwide rights to develop and commercialize Sollpura liprotamase to Anthera. Lilly is...
...it plans to sublicense all rights, obligations and IP for the development and commercialization of Sollpura...

...that it discontinued development of liprotamase. In 2011, FDA issued a complete response letter for liprotamase...
...The product is a combination of 3 types of microbially derived pancreatic enzymes. Lilly gained liprotamase...
...2010 (see BioCentury, July 26, 2010). Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Liprotamase (LY3031642...

...diabetes. Altus Biologics Inc. discontinued development of the oral cross-linked pancreatic enzyme crystal biologic Trizytek liprotamase...